No association of the 5' promoter region polymorphism of CYP17 gene with prostate cancer risk

Prostate Cancer Prostatic Dis. 2002;5(1):28-31. doi: 10.1038/sj.pcan.4500550.

Abstract

CYP17 gene encodes the enzyme cytochrome p450c17alpha, which mediates two steps in the steroid biosynthesis pathway. Steroid hormones are believed to play a key role in the etiology of prostate cancer. A polymorphic T-->C transition in the 5(') promoter region of CYP17 creates an additional Sp1-type (CCACC box) promoter site (allele A2). We have evaluated the genotypic and allelic distribution of this polymorphism among 92 prostate cancer patients in order to assess risk by comparison with a population-based series of 200 healthy individuals from Brazil. Our results provide no evidence for an association between prostate cancer risk and CYP17 T/C polymorphism.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adult
  • Aged
  • Brazil / epidemiology
  • Case-Control Studies
  • Gene Frequency
  • Genetic Predisposition to Disease*
  • Genotype
  • Humans
  • Male
  • Polymerase Chain Reaction
  • Polymorphism, Genetic*
  • Polymorphism, Restriction Fragment Length
  • Promoter Regions, Genetic / genetics*
  • Prostate / metabolism*
  • Prostate / pathology
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / epidemiology
  • Prostatic Neoplasms / genetics*
  • Risk Factors
  • Steroid 17-alpha-Hydroxylase / blood
  • Steroid 17-alpha-Hydroxylase / genetics*

Substances

  • Steroid 17-alpha-Hydroxylase